In:
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, SAGE Publications, Vol. 55, No. 4 ( 2018-07), p. 430-436
Abstract:
There are limited data regarding the contribution of advanced glycation end products in the presence of rheumatoid arthritis. We investigated whether serum N ɛ -carboxymethyllysine and pentosidine were related to the presence and the severity of rheumatoid arthritis. Methods Eighty patients with rheumatoid arthritis and 30 control subjects were included in a cross-sectional study. The severity of rheumatoid arthritis was assessed using the disease activity score for 28 joints. Serum N ɛ -carboxymethyllysine and pentosidine were measured by enzyme-linked immunosorbent assay. Results Serum N ɛ -carboxymethyllysine and pentosidine concentrations were significantly higher in patients with rheumatoid arthritis vs. control subjects ( P 〈 0.001). Serum N ɛ -carboxymethyllysine and pentosidine concentrations were significantly higher in rheumatoid arthritis patients with high disease activity vs. rheumatoid arthritis patients with moderate disease activity ( P 〈 0.001, P = 0.019, respectively). A multiple logistic regression analysis demonstrated that N ɛ -carboxymethyllysine was independently associated with the presence of rheumatoid arthritis (OR = 1.21, 95% CI: 1.05–1.39, P = 0.006). Furthermore, in a multivariate stepwise regression analysis, N ɛ -carboxymethyllysine was independently correlated with disease activity score for 28 joints (standardized β = 0.43, P = 0.001). Conclusion Serum N ɛ -carboxymethyllysine and pentosidine were increased during rheumatoid arthritis, and N ɛ -carboxymethyllysine was independently associated with the presence and the severity of rheumatoid arthritis.
Type of Medium:
Online Resource
ISSN:
0004-5632
,
1758-1001
DOI:
10.1177/0004563217733500
Language:
English
Publisher:
SAGE Publications
Publication Date:
2018
detail.hit.zdb_id:
2041298-8
Permalink
